Corrigendum
- PMID: 29923421
- DOI: 10.1177/1479164118775894
Corrigendum
Abstract
Gaspari T, Spizzo I, Liu HB, et al. (2018) Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diabetes & Vascular Disease Research 2018; 15(1): 64-73. DOI: 10.1177/1479164117733626 The authors have highlighted a typographical error which exists in the NFκB reverse primer sequence outlined in the paper. The published NFκB reverse primer sequence reads 5'-TGT-CGT-GCT-CCA-CAC-AGC-CAG-GT-3'. The correct sequence for the NFκB reverse primer sequence should read 5'-TGT-CGT-GCT-CCA-CAG-CCA-GGT-3'. The correct NFκB primer sequence was the sequence utilised in production of the NFκB reverse primer used in all PCR experiments undertaken in this study and thus does not impact on the validity of the PCR results.
Erratum for
- 
  
  Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.Diab Vasc Dis Res. 2018 Jan;15(1):64-73. doi: 10.1177/1479164117733626. Epub 2017 Oct 4. Diab Vasc Dis Res. 2018. PMID: 28976221
Publication types
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Miscellaneous
 
        